Cumbo Alexander 4

What Happened
Alexander Cumbo, a director of Vor Biopharma (VOR), was granted a derivative award on June 11, 2026 covering 56,345 shares at a reported price of $0.00 (no cash paid). The filing classifies the transaction as an award/grant (derivative), so this is not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-11; filing date: 2026-06-12 (timely filed).
• Award size: 56,345 shares; reported price: $0.00; reported value: $0 (derivative award).
• Vesting: One thirty-sixth of the shares subject to the award vests on July 11, 2026 and one thirty-sixth vests each month thereafter, subject to continued service (36 monthly installments).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing type/transaction code: Derivative award (transaction code A). No 10b5-1 plan or tax-withholding note was disclosed in the excerpt.

Context
Director awards like this are commonly used for compensation and typically vest over time to encourage continued service; they are not the same signal as an open-market purchase. Because this is an award (not a sale), it should be viewed as routine director compensation rather than a direct bullish or bearish market action.